Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (8)
Language
- English (8)
Keywords
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- multiple sclerosis (3)
- Autoantibodies (2)
- Cerebrospinal fluid (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- Multiple sclerosis (2)
- optical coherence tomography (2)
- Antibody index (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Ataxia (1)
- Azathioprine (1)
- Barkhof criteria (1)
- Brainstem encephalitis (1)
- Cell-based assays (1)
- Cerebellitis (1)
- Devic syndrome (1)
- Devic’s syndrome (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Electrophysiology (1)
- Evoked potentials (1)
- Facial nerve palsy (1)
- Glatiramer acetate (1)
- Hearing loss (1)
- IL-22 binding protein isoform (1)
- IL22RA2 (1)
- IPND criteria (1)
- Infections (1)
- Interferon beta (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Longitudinally extensive transverse myelitis (1)
- MOG-IgG (1)
- Magnetic resonance imaging (1)
- McDonald criteria (1)
- Methotrexate (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelitis (1)
- NMO-IGG (1)
- NMO-IgG (1)
- Natalizumab (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Outcome (1)
- Pregnancy (1)
- Respiratory insufficiency (1)
- Rhombencephalitis (1)
- Rituximab (1)
- Therapy (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Treatment (1)
- Vaccination (1)
- Wingerchuk criteria 2006 and 2015 (1)
- anti-aquaporin-4 antibody (1)
- antibodies (1)
- aquaporin-4 antibodies (AQP4-IgG) (1)
- aquaporin-4 autoantibodies (1)
- artery occlusion (1)
- association (1)
- autoimmune (1)
- brain (1)
- cerebrospinal-fluid (1)
- endotheliopathy (1)
- extensiv transverse myelitis (1)
- genetics (1)
- hearing loss (1)
- immune-response (1)
- immunoglobulin-G (1)
- intractable hiccup (1)
- linkage (1)
- microangiopathy (1)
- multiple-sclerosis (1)
- mutation (1)
- myasthenia gravis (1)
- neuromyelitis optica (1)
- neuromyelitis optica spectrum disorders (NMOSD) (1)
- optic neuritis (1)
- plasminogen (1)
- retinal neuro-axonal damage (1)
- retinocochleocerebral (1)
- signal peptide (1)
- vasculopathy (1)
- visual acuity (1)
- visual evoked potentials (1)
Institute
Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here, we describe the characterization of a multi-incident MS family that nominated a rare missense variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of PLG p.G420D (rs139071351) in 2160 MS patients, and 886 controls from Canada, identified 10 additional probands, two sporadic patients and one control with the variant. Segregation in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family members diagnosed with MS, 14 unaffected parents, and 12 out of 30 family members not diagnosed with disease. Despite considerably reduced penetrance, linkage analysis supports cosegregation of PLG p.G420D and disease. Genotyping of PLG p.G420D in 14446 patients, and 8797 controls from Canada, France, Spain, Germany, Belgium, and Austria failed to identify significant association with disease (P = 0.117), despite an overall higher prevalence in patients (OR = 1.32; 95% CI = 0.93–1.87). To assess whether additional rare variants have an effect on MS risk, we sequenced PLG in 293 probands, and genotyped all rare variants in cases and controls. This analysis identified nine rare missense variants, and although three of them were exclusively observed in MS patients, segregation does not support pathogenicity. PLG is a plausible biological candidate for MS owing to its involvement in immune system response, blood-brain barrier permeability, and myelin degradation. Moreover, components of its activation cascade have been shown to present increased activity or expression in MS patients compared to controls; further studies are needed to clarify whether PLG is involved in MS susceptibility.